Students in leadership positions learn about brain tumors and gain real world experience in running a non-profit business while raising funds for brain tumor research. Beneficiaries of the money we raise are Barrow Neurological Institute, National Brain Tumor Society, Phoenix Children's Hospital, Translational Genomics Research Institute, and University of Arizona.

"Be the change you wish to see in the world..." Gandhi

Our Beneficiaries

  • University of AZ Research Centers
    University of AZ Research Centers
  • “It is every man's obligation to put back into the world at least the equivalent of what he takes out of it.”

    — Albert Einstein

Brain Tumor News

A new blood test that can detect brain cancer has been developed in the United Kingdom. It’s cutting edge technology uses artificial intelligence and has a high accuracy rate. This new blood test sounds very promising. Now what the researchers did was to use an infrared light technique to produce what’s called a biochemical ‘fingerprint’.

A new blood test that can detect brain cancer has been developed in the United Kingdom. It’s cutting edge technology uses artificial intelligence and has a high accuracy rate. This new blood test sounds very promising. Now what the researchers did was to

Researchers for the University of Strathclyde have developed the test, which uses infrared light to produce a "bio-signature" of a blood sample and applies artificial intelligence to check for the signs of cancer.

Researchers at Tufts University have just developed a way to create an environment that closely mimics that of the brain and were able to grow pediatric and adult tumors within it. The microenvironment allows for non-invasive imaging of the tumors and for easy manipulation of the cells growing within.

Tiny bubbles in the brain might offer some respite for some. An experiment using those bubbles to help treatment drugs get to places normally out of reach. The technique could give patients with glioblastomas far longer lives. It could also offer a way to treat other devastating brain diseases such as Alzheimer’s and Parkinson’s.

Ribociclib, a drug that was recently FDA-approved for breast cancer, is part of a new class of drugs that target cell division thereby suppressing cancer progression.

The Ivy Brain Tumor Center at Barrow Neurological Institute, today announced a new collaboration with QED Therapeutics, Inc., a subsidiary of BridgeBio Pharma, Inc., (Nasdaq:BBIO) to investigate the FGFR1-3 tyrosine kinase inhibitor, infigratinib, for the treatment of glioblastoma (GBM).

View Previous News Articles - Click Here!